iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes
Status:
Withdrawn
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This open-label, randomized, parallel group phase II study will investigate the efficacy of
computational biology-informed treatment vs. standard of care treatment for patients with
relapsed or refractory myelodysplastic syndromes (MDS).